The stock of Fibrocell Science Inc (NASDAQ:FCSC) reached all time high today, Nov, 24 and still has GBX 1.03 target or 8.00% above today’s GBX 0.95 share price. This indicates more upside for the GBX 45.04M company. This technical setup was reported by Barchart.com. If the GBX 1.03 PT is reached, the company will be worth GBX 3.60M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. The stock 0.01% or $0 on November 23, hitting $0.95. It is up 71.39% since April 22, 2016 and is downtrending. It has underperformed by 76.79% the S&P500.
Fibrocell Science Inc (NASDAQ:FCSC) Ratings Coverage
Out of 3 analysts covering Fibrocell Science (NASDAQ:FCSC), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Fibrocell Science has been the topic of 3 analyst reports since September 28, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Roth Capital given on Tuesday, December 22. The rating was initiated by TH Capital with “Buy” on Tuesday, December 22. The stock has “Neutral” rating given by Wedbush on Monday, September 28.
Another recent and important Fibrocell Science Inc (NASDAQ:FCSC) news was published by Marketwatch.com which published an article titled: “Fibrocell Science stock price target cut to $4 from $6 at Wedbush Securities” on April 17, 2011.
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The company has a market cap of $45.04 million. The Firm is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. It currently has negative earnings. The Company’s product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.